19930105
 MedImmune shares fall 17% on Merck's AIDS drug review   The Wall Street Journal,  Jan 6, 1993  Biotechnology concern MedImmune's shares fell more than 17% on Jan 5, 1993 to $19.25, off $4, on news that Merck & Co is evaluating whether to continue their collaboration on a possible vaccine against the AIDS virus.   
